Q-omics provides the consensus-scored TTC17 profile across patient tissues and cancer cell-line models. TTC17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TTC17 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TTC17 RNA expression shows 21,383 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where TTC17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC17 survival associations across molecular data types. TTC17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC17 RNA expression–survival associations across cancer types. High TTC17 expression shows unfavorable associations in KIRP, CESC, KICH, ACC and BLCA, but favorable associations in UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TTC17 RNA expression.
This table summarizes TTC17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC17 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, STAD, LIHC and KIRP. The HNSC box plot shows higher TTC17 RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with TTC17 in patient tissues and cancer cell lines. In patient samples, TTC17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
